百诚医药：与众神创新就创新药BIOS-0629项目达成大中华地区独家授权合作，交易金额3亿元

Core Viewpoint - The company has entered into an exclusive collaboration with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. for the innovative drug BIOS-0629 in the Greater China region, which includes mainland China and Hong Kong, Macau, and Taiwan [1] Group 1 - The collaboration agreement includes a milestone payment of 300 million yuan upon reaching specific research and development milestones [1] - The agreement will take effect after approval from the company's shareholders' meeting [1] - The company will receive a 10% commission on sales revenue once the product is launched in the Greater China region [1]